Meet the 2021 Laureates: Richard J.M. Ross, MBBS, MD, FRCP

Richard Ross-420

Outstanding Innovation Award 

Richard J.M. Ross, MBBS, MD, FRCP


Richard J. Ross is an exceptional clinical scientist in the tradition of clinical scientists addressing the unmet needs of patients and translating these from bed to bench and back as innovative drugs.

His research on optimizing endocrine replacement therapy has focused on replacement of cortisol in patients with adrenal insufficiency (AI) and congenital adrenal hyperplasia (CAH). In 2000, he established the CAH Adult Study Executive (CaHASE), which through high impact publications in The Journal of Clinical Endocrinology & Metabolism, highlighted the poor health outcomes in adults with CAH due to inadequate glucocorticoid replacement. Based on this, and through extensive work examining the pharmacokinetics of hydrocortisone, Richard developed a novel formulation, Chronocort, and tested this through Phase 1 – 3 clinical trials demonstrating that Chronocort could replace the cortisol circadian rhythm and improve the disease control of CAH patients. To develop Chronocort, Richard Founded a company, Diurnal Plc, floated it on the London stock market, and the company has submitted a Market authorization for Chronocort in Europe and opened an IND in the U.S.

Between 2010 and 2017, Richard led the TAIN (Treatment of Adrenal Insufficiency in Neonates) consortium, which surveyed clinicians and patients to understand the unmet need in pediatric adrenal insufficiency. Based on this work, the consortium developed a new pediatric hydrocortisone formulation, Infacort. The formulation was tested in innovative clinical trials in neonates, infants, and children with adrenal insufficiency. In 2018, Diurnal Plc, for which Richard is now chief scientific officer, was granted a Pediatric Use Market Authorization in Europe (brand name Alkindi®) and is now the subject of an NDA with the FDA. Richard is one of only a few clinical scientists who has founded an endocrine pharmaceutical company that has not only developed new therapies but also commercialized those therapies for patients.

You may also like

  • New Position Statement Focuses on Patient Experience in Diabetes Care

    Healthcare providers who treat diabetes need to think beyond the clinical numbers, such as solely focusing on a person’s glucose goals. Taking the patient experience into account can improve the quality of care and facilitate attainment of treatment goals, according to a new position statement published in the Endocrine Society’s Journal of Clinical Endocrinology &…

  • Felix Beuschlein Receives 2024 Transatlantic Alliance Award in Endocrinology 

    The Endocrine Society and the European Society of Endocrinology (ESE) are delighted to announce that they have awarded the 2024 Transatlantic Alliance Award to Professor Felix Beuschlein, MD.  Beuschlein is professor of internal medicine/endocrinology and director of the Clinic for Endocrinology, Diabetology, and Clinical Nutrition at the University Clinic Zurich in Switzerland. He received his…

Find more in